Orion Oyj banner

Intrinsic Value

The intrinsic value of Orion Oyj (OFK) under the Base Case is 74.34 EUR per share. Compared with the current market price of 99.15 EUR, the stock appears Overvalued by 25% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

OFK Intrinsic Value
€74.34
Overvaluation 25%
Intrinsic Value
Price €99.15

OFK is more expensive than usual. It was this expensive or more expensive on just 3% of days in the past 5 years.

Alert me when OFK is below its intrinsic value
Today €59.48 · 40.0% below the current price
Alternatives to OFK

Fundamental Analysis

What Orion Does

Pharmaceuticals Health Care

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and sells medicines for people and animals. Its main products include prescription drugs, over-the-counter medicines, and veterinary medicines, with a strong focus on treatments for the central nervous system, cancer care, and animal health. The company also makes active pharmaceutical ingredients and other drug-related products that it sells to partners in the healthcare industry.

Headquarters
Finland FI
Employees
4 132
IPO date
Jul 3, 2006
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · October 28, 2026

Nubeqa remained Orion’s key growth driver, and strong first-nine-month performance and outlook for the rest of the year prompted an upgrade to its 2026 financial outlook.

Open the earnings call
EPS
€1.19
Expected
€1.13
Surprise
+5.3%
Stock, day of the call
+0.2%
View Earnings Call

Past 12 months

Continue OFK Research

Decided on Orion? Get an email when OFK reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one OFK stock?

The intrinsic value for Orion Oyj (OFK) under the Base Case is 74.34 EUR.

Is OFK stock undervalued or overvalued?

Compared with the current market price of 99.15 EUR, the stock appears Overvalued by 25% .

How reliable are our estimates? See how past valuations played out
Back to Top